DTech Liquidating

DTech Liquidating Financial Leverage

Delisted

The Financial Leverage (Equity Multiplier) of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is 2.13. In the previous year, Financial Leverage (Equity Multiplier) was 1.53 — a change of 39.71% (higher).

Financial Leverage

2.13

YoY

39.71%

Last updated:

Financial Leverage (Equity Multiplier) of DTech Liquidating is 2023 2.13 . Financial Leverage (Equity Multiplier) of DTech Liquidating was 2022 1.53 . It decreases by 39.71% higher compared to the previous year.

The DTech Liquidating Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2017
1.04 USD
Jan 1, 2018
2.10 USD
Jan 1, 2019
1.46 USD
Jan 1, 2020
1.10 USD
Jan 1, 2021
1.08 USD
Jan 1, 2022
1.53 USD
Jan 1, 2023
2.13 USD
The DTech Liquidating Financial Leverage history
YEARFinancial LeverageYoY
2.13+39.71%
1.53+41.21%
1.08-1.66%
1.10-24.50%
1.46-30.72%
2.10+102.87%
1.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Financial Leverage (Equity Multiplier) of DTech Liquidating is 2.13 in 2023.

Financial Leverage (Equity Multiplier) of DTech Liquidating changed from 1.53 to 2.13, representing a 39.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — DTech Liquidating

All Key Metrics — DTech Liquidating